The latest price target for Cyclacel Pharmaceuticals (NASDAQ:CYCC) was reported by Roth MKM on May 3, 2024. The analyst firm set a price target for $11.00 expecting CYCC to rise to within 12 months (a possible 1021.30% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Cyclacel Pharmaceuticals (NASDAQ:CYCC) was provided by Roth MKM, and Cyclacel Pharmaceuticals maintained their buy rating.

There is no last upgrade for Cyclacel Pharmaceuticals

The last downgrade for Cyclacel Pharmaceuticals Inc happened on December 19, 2023 when Brookline Capital changed their price target from N/A to N/A for Cyclacel Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cyclacel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cyclacel Pharmaceuticals was filed on May 3, 2024 so you should expect the next rating to be made available sometime around May 3, 2025.

While ratings are subjective and will change, the latest Cyclacel Pharmaceuticals (CYCC) rating was a maintained with a price target of $21.00 to $11.00. The current price Cyclacel Pharmaceuticals (CYCC) is trading at is $0.98, which is out of the analyst’s predicted range.